Biblio

Export 2657 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2015
L. Calderón-Garcidueñas, Mora-Tiscareño, A., Sánchez, G. Melo, Rodríguez-Díaz, J., Torres-Jardón, R., Styner, M., Mukherjee, P. S., Lin, W., and Jewells, V., “A Critical Proton MR Spectroscopy Marker of Alzheimer's Disease Early Neurodegenerative Change: Low Hippocampal NAA/Cr Ratio Impacts APOE ɛ4 Mexico City Children and Their Parents.”, J Alzheimers Dis, 2015.
N. J. Donovan, Hsu, D. C., Dagley, A. S., Schultz, A. P., Amariglio, R. E., Mormino, E. C., Okereke, O. I., Rentz, D. M., Johnson, K. A., Sperling, R. A., and Marshall, G. A., “Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.”, J Alzheimers Dis, 2015.
N. J. Donovan, Hsu, D. C., Dagley, A. S., Schultz, A. P., Amariglio, R. E., Mormino, E. C., Okereke, O. I., Rentz, D. M., Johnson, K. A., Sperling, R. A., and Marshall, G. A., “Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.”, J Alzheimers Dis, 2015.
E. Moyse, Bastin, C., Salmon, E., and Brédart, S., “Impairment of Age Estimation from Faces in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
N. Kemppainen, Joutsa, J., Johansson, J., Scheinin, N. M., Någren, K., Rokka, J., Parkkola, R., and Rinne, J. O., “Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 48, no. 1, pp. 123-33, 2015.
R. Remington, Bechtel, C., Larsen, D., Samar, A., Doshanjh, L., Fishman, P., Luo, Y., Smyers, K., Page, R., Morrell, C., and Shea, T. B., “A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
R. Remington, Bechtel, C., Larsen, D., Samar, A., Doshanjh, L., Fishman, P., Luo, Y., Smyers, K., Page, R., Morrell, C., and Shea, T. B., “A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
R. Remington, Bechtel, C., Larsen, D., Samar, A., Doshanjh, L., Fishman, P., Luo, Y., Smyers, K., Page, R., Morrell, C., and Shea, T. B., “A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
C. Peters-Libeu, Campagna, J., Mitsumori, M., Poksay, K. S., Spilman, P., Sabogal, A., Bredesen, D. E., and John, V., “sAβPPα is a Potent Endogenous Inhibitor of BACE1.”, J Alzheimers Dis, vol. 47, no. 3, pp. 545-55, 2015.
C. Peters-Libeu, Campagna, J., Mitsumori, M., Poksay, K. S., Spilman, P., Sabogal, A., Bredesen, D. E., and John, V., “sAβPPα is a Potent Endogenous Inhibitor of BACE1.”, J Alzheimers Dis, vol. 47, no. 3, pp. 545-55, 2015.
E. C. Edmonds, Delano-Wood, L., Galasko, D. R., Salmon, D. P., and Bondi, M. W., “Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 1, pp. 231-42, 2015.
C. B. Malpas, Saling, M. M., Velakoulis, D., Desmond, P., and O'Brien, T. J., “Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 47, no. 4, pp. 965-75, 2015.
2014
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
A. R. Haeusler, Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M. - S., Maragakis, N. J., Troncoso, J. C., Pandey, A., Sattler, R., Rothstein, J. D., and Wang, J., “C9orf72 nucleotide repeat structures initiate molecular cascades of disease.”, Nature, vol. 507, no. 7491, pp. 195-200, 2014.
A. R. Haeusler, Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M. - S., Maragakis, N. J., Troncoso, J. C., Pandey, A., Sattler, R., Rothstein, J. D., and Wang, J., “C9orf72 nucleotide repeat structures initiate molecular cascades of disease.”, Nature, vol. 507, no. 7491, pp. 195-200, 2014.
A. R. Haeusler, Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M. - S., Maragakis, N. J., Troncoso, J. C., Pandey, A., Sattler, R., Rothstein, J. D., and Wang, J., “C9orf72 nucleotide repeat structures initiate molecular cascades of disease.”, Nature, vol. 507, no. 7491, pp. 195-200, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
S. Hoon Choi, Kim, Y. Hye, Hebisch, M., Sliwinski, C., Lee, S., D'Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., and Kim, D. Yeon, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.

Pages